

AD _____

Award Number: DAMD17-99-1-9115

TITLE: TIG3 - A Novel Inhibitor of Breast Cancer Cell
Proliferation

PRINCIPAL INVESTIGATOR: Richard L. Eckert, Ph.D.

CONTRACTING ORGANIZATION: Case Western Reserve University
Cleveland, Ohio 44106-7015

REPORT DATE: September 2002

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030411 018

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE September 2002	3. REPORT TYPE AND DATES COVERED Annual (1 Sep 01 - 31 Aug 02)	
4. TITLE AND SUBTITLE TIG3 - A Novel Inhibitor of Breast Cancer Cell Proliferation			5. FUNDING NUMBERS DAMD17-99-1-9115	
6. AUTHOR(S) Richard L. Eckert, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Case Western Reserve University Cleveland, Ohio 44106-7015 E-Mail: rie2@po.cwru.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) The mechanism of inhibition of cancer cell proliferation by vitamin A is poorly understood because many of the targets that mediate the retinoid-dependent growth suppression are not known. We have recently identified a novel retinoid-responsive gene target, TIG3, that we believe may be a key player in mediating the retinoid-dependent suppression of tumor cell proliferation. Understanding the mechanism of TIG3 action may provide insights that lead to innovative new anti-breast cancer therapies. Exploiting this potential requires that we understand how TIG3 inhibits cell proliferation - the major goal of this proposal. <i>Specific Aim 1</i> Subcellular location plays a major role in determining function, and knowing location provides clues about function. Therefore, our first goal is to localize TIG3 in breast cancer cells. <i>Specific Aim 2</i> Most proteins contain distinct functional domains, some responsible for localization and others for function. We hypothesize that TIG3 is divided into distinct functional domains that are important for growth suppression. We are testing this hypothesis. <i>Specific Aim 3</i> The TIG3 amino acid sequence/structure reveals no obvious catalytic functional domains, suggesting that TIG3 acts by modulating the function of other proteins. A major goal of the study is to identify these targets. During the first year we have 1) constructed a plasmid-based TIG3 expression systems and used it to express TIG3 in cells, 2) identified a perinuclear localization of TIG3 in cells, 3) demonstrated that the TIG3 carboxy-terminal hydrophobic domain guides appropriate subcellular localization, 4) shown that the TIG3 carboxy-terminal tail is required for optimal cell killing, and 5) constructed an adenovirus expression system that permits efficient TIG3 expression for biochemical studies.				
14. SUBJECT TERMS breast cancer			15. NUMBER OF PAGES 9	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

TABLE OF CONTENTS (1 page)

SECTION	PAGES
Cover	1
SF 298	2
Table of Contents	3
Introduction	4
Body	4
Key Research Accomplishments	8
Reportable Outcomes	9
Conclusions	9
References	9
Appendices	-

INTRODUCTION

The mechanism whereby vitamin A analogs inhibit breast cancer cell proliferation is not known. We have identified a retinoid-regulated gene, **TIG3**, that we believe may be a key mediator of retinoid-dependent suppression of breast tumor cell growth. Vitamin A treatment increases TIG3 mRNA levels in breast tumor cells, and this is correlated with growth suppression, suggesting that TIG3 may mediate the retinoid-dependent suppression. Understanding how TIG3 works may lead to innovative new anti-breast cancer therapies. Exploiting this potential requires that we understand how TIG3 inhibits cell proliferation - the major goal of this proposal. **Specific Aim 1** The goal of this aim is to localize TIG3 subcellular distribution. We have localized TIG3 distribution to the perinuclear region and shown that it localizes in membrane structures via its carboxyl terminus. **Specific Aim 2** We hypothesize that TIG3 is divided into distinct functional domains that are important for growth suppression. We have tested a variety of mutants and have identified critical regulatory domains. **Specific Aim 3** The TIG3 amino acid sequence/structure reveals no obvious catalytic functional domains, suggesting that TIG3 acts by modulating the function of other proteins. The goal of this specific aim is to identify candidate target proteins using co-immunoprecipitation, affinity chromatography and two-hybrid screening. We have made considerable progress with the first two specific aims, but we need continued effort to complete the goals addressed in specific aim three.

BODY

Specific Aims 1 & 2

- *Subcellular location plays a major role in determining function, and knowing location provides clues about function. Therefore, our first goal is to use immunological and cell fractionation methods to localize TIG3 in cells.*
- *Most proteins contain distinct functional domains, some responsible for localization and others for function. We hypothesize that TIG3 is divided into distinct functional domains that are important for growth suppression. To test this, we will construct a series of mutants and measure the ability of each mutant to suppress growth using a breast cancer cell colony formation assay.*

We will describe the construction of our TIG3 mutants, their detection in cells, and their subcellular distribution, and their bioactivity in this section. One manuscript has been published based on this work. A second manuscript is accepted in the *Journal of Biological Chemistry* (pending minor revision), and several more are planned.

Construction of TIG3 inducible adenovirus expression constructs TIG3 is an 18 kDa 164 amino acid growth suppressor protein that is present in very low levels in cells. An important goal of this study is to identify the role of various functional domains within the protein and to determine which domain controls subcellular localization. The sequence of TIG3 is shown in **Fig. 1**.

10	20	30	40	50
MASPHQEPKP	GDLEIEIFGRLG	YEHWALYIGD	GYVIHLAPPS	EYPGAGSSSV
60	70	80	90	100
FSVLSNASAEV	KRGRLEDVVG	GCCYRVNNSL	DHEYQPRPVE	VISSAKEMV
110	120	130	140	150
GQKMKYSIVS	RNCEHFVAQL	RYGKSRCKQV	EKAKVEVGVA	TALGILVAG
160				
CSFAIRRYQK	KATA			

Fig. 1 Structure of TIG3. The amino terminal segment encodes amino acids 1-134, while the carboxy terminal tail includes amino acids 135-164.

The protein is divided into an amino-terminal domain and a carboxy-terminal hydrophobic domain. We hypothesize that TIG3 subcellular distribution is controlled by the carboxy-terminal hydrophobic domain and that this serves to anchor TIG3 to membranes. We further hypothesize that various conserved domains in the amino terminus

are required to mediate the growth inhibitory effects. To test this idea we constructed the mutants shown in **Fig. 2**. TIG3₁₋₁₆₄ encodes the full-length protein, while TIG3₁₋₁₃₄ encodes the TIG3 amino-terminus but lacks the carboxy-terminal tail. In the previous report, we described studies showing that TIG3₁₋₁₆₄ efficiently inhibits proliferation, while TIG3₁₋₁₃₄ is minimally effective [2613]. Thus, these studies showed that the carboxyl terminal domain is required for activity. These studies also revealed that TIG3 is localized in the perinuclear region in cells [2613]. These early studies were performed using plasmid-based expression systems that were not very efficient in that transfection would only target 10% of cells in a dish. This plasmid-based system required elaborate selection protocols to quantitate cell kill results [2613]. To circumvent this problem, we subcloned full-length TIG3 (TIG3₁₋₁₆₄), and all of the other mutants shown in **Fig. 2** into an inducible adenovirus vector, tAd5. This expression system relies on infection with two viruses – one virus that expresses the protein of interest, and a second virus that produces the TET activator protein (Ad5-TA). The TET activator (TA) binds to the promoter in the expression virus to regulate expression. In addition, the TET activator can be inactivated when tetracycline is present in the medium. Thus, expression of TIG3 can be expressed in a regulated manner. This system has two major advantages. First, it delivers protein by infection and, therefore, virtually 100% of the cells can express the protein.





Fig. 2 TIG3 expression constructs. The various TIG3 encoding segments were synthesized using PCR and then cloned into the tAd5 adenovirus. The resulting recombinant adenoviruses encode the indicated TIG3 mutants. The top construct is full-length TIG3 (TIG3₁₋₁₆₄). Each of the other constructs has been modified by truncation from the carboxyl or amino-terminal ends. In addition, we have added specific epitope tags to the amino terminal end in most of the constructs (FLAG or HA). Antibodies are available that detect each of these epitopes. The vertical hatches represent areas of conservation with other members of the TIG3 family of proteins [2613].

Second, the level of TIG3 per cell can be regulated by the level of tetracycline present in the cell culture medium. Additional studies (not shown) indicate that each of the mutant TIG3 proteins encoded by the viruses shown in **Fig. 2** are expressed in virus-infected breast cancer cells. Expression was detected by immunoblot using anti-FLAG, anti-HA, and/or anti-TIG3 antibodies. Each virus was optimized regarding infection ratio etc. so that 100% of the cells are infected and express the TIG3 protein.

TIG3 associates with membranes via its carboxyl terminal hydrophobic domain Using immunohistology, we have demonstrated that full-length TIG3 localizes in the perinuclear region in cells. **Fig. 3** shows this result for CHO cells. A similar subcellular distribution of full-length (TIG3₁₋₁₆₄) is observed using the adenovirus-based delivery in a variety of cells, including T₄₇D breast cancer cells and SK-BR-3 cells. In the most recent funding period, we have tested the other mutants shown in **Fig. 2**. All of the amino-terminal truncation mutants (TIG3₄₁₋₁₆₄, TIF3₁₀₀₋₁₆₄, TIG3₁₁₂₋₁₆₄, and TIG3₁₂₄₋₁₆₄) localize with membranes with a distribution similar to full-length TIG3 (TIG3₁₋₁₆₄). Only, the C-terminal truncation mutants, TIG3₁₋₁₅₇ and TIG₁₋₁₃₄ do not localize with membranes - these mutants are present diffusely throughout the cytoplasm.



Based on these studies, we conclude that the hydrophobic carboxyl end localizes TIG3 to membranes.

Fig. 3 Subcellular localization of TIG3₁₋₁₆₄ and TIG3₁₋₁₃₄ in CHO cells. Cells were transfected with expression plasmid encoding TIG3₁₋₁₆₄ (panels A and B) or TIG3₁₋₁₃₄ (panel B). Cells in panel B were additionally treated with cycloheximide {2613}. CHO cells were chosen as an initial test cell since they are easily transfected.

Regulation of breast cancer cell proliferation by TIG3

We next evaluated the effects of each mutant on cell proliferation and survival. Cells were plated in 35 mm dishes and allowed to attach overnight and then infected with 0 – 150 MOI of adenovirus. The virus was then removed and incubation was continued for an additional 60 h at which time the cells were harvested and assessed for viability. **Fig. 4A** shows that SK-BR-3 cell number is dramatically reduced by TIG3₁₋₁₆₄ expression. Cell number is 50% reduced at an MOI = 50, and 90% at MOI \geq 75. **Fig. 4B** shows that the growth suppression is directly correlated with increased TIG3₁₋₁₆₄ expression. In parallel studies, we examined the ability of the TIG3 mutants shown in **Fig. 2** to suppress cell proliferation/survival. Our results are shown in **Table 1**. The growth suppression observed with the TIG3 mutants is compared to that observed when cells are infected with empty adenovirus (tAd5-EV).





Fig. 4 TIG3 reduces SK-BR-3 cell survival. **A** SK-BR-3 cells were plated, permitted to attach overnight, and then treated with 0 – 150 MOI of tAd5-TIG31-164 for 12 h and the virus was removed. After an additional 60 h, the cells were harvested and counted. Percent cell survival at each MOI is calculated by comparison to a group containing an identical amount of tAd5-EV (empty virus). **B** Total cell extracts were prepared from cells treated as above, and then electrophoresed on an 8% gel for immunoblotting with rabbit anti-human TIG3. β -actin was included as a control blot to assure equal loading of protein.

Essentially, all of the mutations result in a significant loss of TIG3 activity. These findings indicate that two domains are essential for TIG3 function – the carboxy-terminal hydrophobic membrane-anchoring domain, and the first 41 amino acids at the amino terminus. We are presently working to identify specific amino acids required for activity.

TIG3 Construct	Properties	Relative Cell Number (% of control)
tAd5-EV	Empty vector	100 %
tAd5-TIG3 ₁₋₁₆₄	Full-length TIG3	1%
tAd5-TIG3 ₄₁₋₁₆₄	Amino-terminal truncation	100%
tAd5-TIG3 ₁₀₀₋₁₆₄	Amino-terminal truncation	100%
tAd5-TIG3 ₁₁₂₋₁₆₄	Amino-terminal truncation	100%
tAd5-TIG3 ₁₂₄₋₁₆₄	Amino-terminal truncation	100%
tAd5-TIG3 ₁₋₁₅₇	Carboxyl-terminal truncation	50%
tAd5-TIG3 ₁₋₁₃₄	Carboxyl-terminal truncation	100%

Table 1 TIG3 regulation of cell number (100% = no cell death, 0% = no cell survival)

To determine whether the response is reversible, we treated SK-BR-3 cells with 75 MOI of TIG3₁₋₁₆₄-encoding virus for 12 h. This level of TIG3₁₋₁₆₄ produces optimal suppression of proliferation (see Fig. 4A). The virus was

then removed, and cell growth was then continued for the times indicated in Fig. 5. It is clear from this experiment that the cells do not rapidly recover from the treatment with TIG3₁₋₁₆₄, as growth remains markedly suppressed at day four.




Fig. 5 SK-BR-3 cells were treated for 12 h with 75 MOI of tAd5-TIG3₁₋₁₆₄ or tAd5-EV (empty vector). The virus was then removed, and incubation was continued for the indicated number of days post-infection. At each time point the cells were harvested and cell number was determined.

TIG3 promotes apoptosis A major goal of this study is to begin to understand the mechanism whereby TIG3 suppresses human breast cancer cell proliferation. The results summarized in Fig. 4A

suggest that the total number of cells in the culture dish is diminished by TIG3₁₋₁₆₄ treatment. This suggests that in addition to inhibiting cell growth, TIG3 actually reduces the number of cells below the starting level. This suggests that TIG3 actively causes cell death.




Fig. 6 TIG3 expression causes nuclear condensation. SK-BR-3 cells were infected with adenovirus encoding TIG3₁₋₁₆₄ for 12 h. Fresh medium was added and at 24 h and 48 h cells were harvested, fixed (2% paraformaldehyde for 20 min at RT, 100% methanol for 10 min at 4 C), and stained with 1 μ g/ml Hoechst 33258 stain for 10 min at room temperature. Corresponding bright field (left panels) and fluorescent photographs (right panels) are compared. All cells expressed TIG3₁₋₁₆₄ as detected by immunoblot (not shown). Note the compression of many of the nuclei in the TIG3-expressing cells at 48 h. No nuclear compaction was observed in cells expressing the control (empty) adenovirus (not shown).

For this reason, we have examined the hypothesis that TIG3 promotes apoptosis. **Fig. 6** shows an experiment in which SK-BR-3 cells were treated for 24 or 48 h with tAd5-TIG3₁₋₁₆₄. All cells in the tAd5-TIG3₁₋₁₆₄ group expressed TIG3 as measured by immunohistology (not shown). The left panel in each set shows the bright field image of the cell field. The right panel shows the Hoechst-stained nuclei. It is important to note that the nuclei of the cells in the tAd5-EV group are of normal size (not shown). In contrast, the nuclei in many of the cells in the tAd5-TIG3₁₋₁₆₄-infected group at 48 h are reduced in size. These images show that the nuclei are compacted in TIG3-expressing cells, a mark of undergoing apoptosis. In addition, preliminary studies suggest that PARP cleavage occurs in TIG3-expressing cells, providing further evidence that TIG3 induces apoptosis.

Specific Aim 3

- *The TIG3 amino acid sequence/structure reveals no obvious catalytic functional domains, suggesting that TIG3 acts by modulating the function of other proteins. The goal of this specific aim is to identify candidate target proteins using co-immunoprecipitation, affinity chromatography and two-hybrid screening.*

Development of an adenovirus-based TIG3 expression system We have proposed that TIG3 binds to target proteins to regulate cell proliferation and survival. A major goal of this study is to identify proteins that interact with TIG3, in order to understand its mechanism of action. We initiated these studies by expressing TIG3 in cells and preparing cell extracts that could be used for TIG3 antibody pull down experiments. However, a major problem with these studies was the inability to express enough TIG3 protein to make these biochemical experiments possible. This was due to the use of a plasmid-based expression system, and the fact that TIG3 kills cells very efficiently and limits the number of TIG3-expressing cells that can be obtained. To circumvent these difficulties we switched from the plasmid-based to an adenovirus-based expression system. The use of this system has solved the problem of minimal protein expression. In addition, it has solved the problem of cell viability, since we are using an inducible expression system that permits the level of TIG3 to be controlled. We are presently using the adenovirus-based expression system to identify proteins that interact with TIG3. In these experiments, we express TIG3 at high levels in SK-BR-3 breast cancer cells, treat the cells with crosslinking agent (DSP) and then immunoprecipitate the crosslinked complexes. We have affixed HA- and FLAG- epitope tags to the amino terminus of the expressed TIG3 proteins as precipitation anchors (see **Fig. 2**).

KEY RESEARCH ACCOMPLISHMENTS

Previous Report Period

- We have constructed plasmid-based TIG3 expression systems and used these to express TIG3 in cells (*Specific Aims 1 and 2*)
- We have shown that TIG3 assumes a perinuclear location in cells, and that a mutant lacking the carboxyl terminus does not assume this location (*Specific Aim 1*)
- We have demonstrated that the TIG3 carboxy-terminal hydrophobic domain is required for appropriate subcellular localization (*Specific Aim 1*)
- Eliminating the TIG3 carboxy-terminal tail reduces the ability of TIG3 to kill cells (*Specific Aim 2*)

- Adenovirus expression systems have been constructed that permit more efficient studies of cell killing and permits efficient production of TIG3 in cells for biochemical studies (*Specific Aims 1, 2 and 3*). This virus produces high-level expression of TIG3 in MCF7 cells.
- TIG3 kills breast cancer cell lines (e.g., T₄₇D, SK-BR-3) (*Specific Aim 2*)

Present Report Period

- We have extended our results to show that TIG3 expression kills SK-BR-3 breast cancer cells and our findings suggest that TIG3 promotes breast cancer cell apoptosis and activation of transglutaminase activity (*Specific Aim 1*)
- We have constructed a number of TIG3 mutants, and identified the carboxyl-terminal hydrophobic domain and the N-terminal 41 amino acids as essential for function. We are presently identifying specific amino acids that are required for activity (*Specific Aims 1 and 2*)
- We have shown that TIG3 activates apoptosis in some cells and increases transglutaminase activity in other cells - both are associated with different cell death pathways.

REPORTABLE OUTCOMES

- We have a manuscript published, and two additional manuscripts will be submitted later this year.
- Mike Sturniolo, a graduate student, reported on the effects of TIG3 and the International Transglutaminase Conference in Ferrara Italy in September 2002.
- Anne Deucher, an M.D./Ph.D. student has completed her thesis. Fifty percent of the thesis focused on TIG3 function.
- Mike Sturniolo's entire Ph.D. thesis, which is 1/2 completed, will focus exclusively on TIG3.
- Shervin Dashti, an M.D./Ph.D. student, who completed a number of the early TIG3 studies and will be a co-author on several TIG3 papers, recently completed his Ph.D.

CONCLUSIONS

We consider this work to be very important from the point-of-view of future breast cancer therapeutics. Our studies completed to date clearly show that TIG3 inhibits the breast cancer cell proliferation. We also suspect that TIG3 has the ability to kill (cause apoptosis) breast cancer cells independent of its effects on cell proliferation. We expect that by the time these studies are concluded we will have isolated the active domains within the protein that are responsible for these events, and that we will have also tested the ability of TIG3 to kill cells *in vivo* in a human tumor cell model system. We have requested and obtained a one year no cost extension. This extension is required so that we may complete Specific Aim 3 prior to resubmission.

REFERENCES

Deucher A, Nagpal S, Chandraratna AS, DiSepio D, Robinson NA, Dashti SR, Eckert RL (2000) The carboxyl-terminal hydrophobic domain of TIG3, a class II tumor suppressor protein, is required for appropriate cellular localization and optimal biological activity. *Inter. J. Oncology* 17:1195-1203.